Immunotherapeutic approaches in prion disease: Progress, challenges and potential directions

Therapeutic Delivery

Volumn 4, Issue 5, 2013, Pages 615-628

  Brazier, Marcus W ^a,b   Mot, Alexandra I ^a   White, Anthony R ^a   Collins, Steven J ^a,b,c  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

LYMPHOTOXIN BETA RECEPTOR; MONOCLONAL ANTIBODY; MS 8209; PENTOSAN POLYSULFATE; PRION PROTEIN 105 125; PRION PROTEIN 1141 159; PRION PROTEIN 165 178; PRION PROTEIN ANTIBODY; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ADOPTIVE TRANSFER; ALPHA HELIX; AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; CHRONIC WASTING DISEASE; CONTROLLED STUDY; CREUTZFELDT JAKOB DISEASE; HUMAN; HYBRIDOMA; HYBRIDOMA CELL CULTURE; HYDROPHOBICITY; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PASSIVE IMMUNIZATION; PRION DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN STRUCTURE; REVIEW; SCRAPIE;

EID: 84877652384     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.13.30     Document Type: Review

References (108)

1. Knight R, Brazier M, Collins S. Human prion disease: cause, clinical and diagnostic aspects. In: Prions: a Challenge for Science, Medicine and Public Health System. Contributions to Microbiology 2nd Revised Edition. Rabenau HF, Cinatl J, Doerr HW (Eds). Karger, Basel, Switzerland, 11, 72-97 (2004
2. Beringue V, Vilotte JL, Laude H. Prion agent diversity and species barrier. Vet. Res. 39(4), 47 (2008
3. Stohr J, Watts JC, Mensinger ZL et al. Purified and synthetic Alzheimer's amyloid beta (Ab) prions. Proc. Natl Acad. Sci. USA 109(27), 11025-11030 (2012
4. Eisele YS, Obermüller U, Heilbronner G et al. Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidosis. Science 330(6006), 980-982 (2010
5. Wang F, Wang X, Yuan CG, Ma J. Generating a prion with bacterially expressed recombinant prion protein. Science 327(5969), 1132-1135 (2010
6. Prusiner SB, Scott MR, DeArmond SJ, Cohen FE. Prion protein biology. Cell 93(3), 337-348 (1998
7. Knowles TPJ, Waudby CA, Devlin GL et al. An analytical solution to the kinetics of breakable filament assembly. Science 326, 1533-1537 (2009
8. Oesch B, Westaway D, Wälchli M et al. A cellular gene encodes scrapie PrP 27-30 protein. Cell 40(4), 735-746 (1985
9. Linden R, Martins VR, Prado MA et al. Physiology of the prion protein Phys. Rev. 88(2), 673-728 (2008
10. Nishida N, Katamine S, Shigematsu K et al. Prion protein is necessary for latent learning and long-term memory retention. Cell. Mol. Neurobiol. 17(5), 537-545 (1997
11. Criado JR, Sanchez-Alavez M, Conti B et al. Mice devoid of prion protein have cognitive deficits that are rescued by reconstitution of PrP in neurons. Neurobiol. Dis. 19(1-2), 255-265 (2005
12. Bremer J, Baumann F, Tiberi C et al. Axonal prion protein is required for peripheral myelin maintenance. Nat. Neurosci. 13(3), 310-318 (2010
13. Schneider B, Mutel V, Pietri M et al. NADPH oxidase and extracellular regulated kinases are targets of prion protein signaling in neuronal and nonneuronal cells. Proc. Natl Acad. Sci. USA 100(23), 13326-13331 (2003
14. Steele AD, Emsley JG, Ozdinler PH et al. Prion protein (PrPc) positively regulates neural precursor proliferation during developmental and adult mammalian neurogenesis. Proc. Natl Acad. Sci. USA 103(9), 3416-3421 (2006
15. Chiarini LB, Freitas AR, Zanata SM et al. Cellular prion protein transduces neuroprotective signals. EMBO J. 21(13), 3317-3326 (2002
16. Collinge J, Whittington MA, Sidle KC et al. Prion protein is necessary for normal synaptic function. Nature 370(6487), 295-297 (1994
17. Brown DR, Qin K, Herms JW et al. The cellular prion protein binds copper in vivo. Nature 390(6661), 684-687 (1997
18. Zanata SM, Lopes MH, de Oliveira E et al. Stress-inducible protein 1 is a cell surface ligand for cellular prion that triggers neuroprotection. EMBO J. 21(13), 3307-3316 (2002
19. Taylor DR, Hooper NM. The low-density lipoprotein receptor-related protein 1 (LRP1) mediates the endocytosis of the cellular prion protein. Biochem J. 402(1), 17-23 (2007
20. Riek R, Hornemann S, Wider G et al. NMR structure of the mouse prion protein domain PrP(121-231). Nature 382(6587), 180-182 (1996
21. Riek R, Hornemann S, Wider G et al. NMR characterization of the full-length recombinant murine prion protein, mPrP(23-231). FEBS Lett. 413(2), 282-288 (1997
22. Billeter M, Riek R, Wider G et al. Prion protein NMR structure and species barrier for prion diseases. Proc. Natl Acad. Sci. USA 94(14), 7281-7285 (1997
23. Taylor DR, Watt NT, Perera WS et al. Assigning functions to distinct regions of the N-terminus of the prion protein that are involved in its copper-stimulated, clathrin-dependent endocytosis. J. Cell Sci. 118(Pt 21), 5141-5143 (2005
24. Haigh CL, Drew SC, Boland MP et al. Dominant roles of the polybasic proline motif and copper in the PrP23-89-mediated stress protection response. J. Cell Sci. 122(Pt 10), 1518-1528 (2009
25. Garnett AP, Viles JH. Copper binding to the octarepeats of the prion protein. Affinity, specificity, folding, and cooperativity: insights from circular dichroism. J. Biol. Chem. 278(9), 6795-6802 (2003
26. Brazier MW, Davies P, Player E et al. Manganese binding the prion protein. J Biol. Chem. 283(19), 12831-12839 (2008
27. Lauren J, Gimble DA, Nygaard HB et al. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 457(7233), 1128-1132 (2009
28. Pan KM, Baldwin M, Nguyen J et al. Conversion of alpha-helices into beta-sheets features in the formation of the scrapie prion proteins. Proc. Natl Acad. Sci. USA 90(23), 10962-10966 (1993
29. Peretz D, Williamson RA, Matsunaga Y et al. A conformational transition at the N terminus of the prion protein features in formation of the scrapie isoforms. J. Mol. Biol. 273(3), 614-622 (1997
30. Korth C, Stierli B, Streit P et al. Prion (PrPsc)-specific epitope defined by a monoclonal antibody. Nature 390(6655), 74-77 (1997
31. Paramithiotis E, Pinard M, Lawton T et al. A prion protein epitope selective for the pathologically misfolded conformation. Nat. Med. 9(7), 893-899 (2003
32. Kretzschmar HA, Ironside JH, DeArmond SJ et al. Diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Arch. Neurol. 53(9), 913-920 (1996
33. Betmouni S, Perry VH, Gordon JL. Evidence for an early inflammatory response in the central nervous system of mice with scrapie. Neuroscience 74(1), 1-5 (1996
34. Will RG, Ironside JW, Zeidler M et al. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 347(9006), 921-925 (1996
35. Hogquist K, Baldwin T, Jameson S. Central tolerance, learning self-control in the thymus. Nat. Rev. Immunol. 5(10), 772-782 (2005
36. Carnaud C, Bachy V. Cell-based immunotherapy of prion diseases by adoptive transfer of antigen-loaded dendritic cells or antigen-primed CD(4+) T lymphocytes. Prion 4(2), 66-71 (2010
37. Gilman S, Koller M, Black RS et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64(9), 1553-1562 (2005
38. Brazier MW, Wall V, Brazier BW, Masters CL, Collins SJ. Therapeutic interventions ameliorating prion disease. Expert Rev. Anti Infect. Ther. 7(1), 83-105 (2009
39. Doh-Ura K, Ishikawa K, Murakami-Kubo I et al. Treatment of transmissible spongiform encephalopathy by intraventricular drug infusion in animal models. J. Virol. 78(10), 4999-5006 (2004
40. Demaimay R, Adjou K, Lasmézas C et al. Pharmacological studies of a new derivative of amphotericin B, MS-8209, in mouse and hamster scrapie. J. Gen. Virol. 75(Pt 9), 2499-2503 (1994
41. White MD, Farmer M, Mirabile I et al. Single treatment with RNAi against prion protein rescues early neuronal dysfunction and prolongs survival in mice with prion disease. Proc. Natl Acad. Sci USA 105(29), 10238-10243 (2008
42. Z'Graggen WJ, Metz GAS, Kartje GL, Thallmair M, Schwab ME. Functional recovery and enhanced corticofugal plasticity after unilateral pyramidal tract lesion and blockade of myelin-associated neurite growth inhibitors in adult rats. J. Neurosci. 18(12), 4744-4757 (1998
43. Papadopoulos CM, Tsai SY, Alsbiei T et al. Functional recovery and neuroanatomical plasticity following middle cerebral artery occlusion and IN-1 antibody treatment in the adult rat. Ann. Neurol. 51, 433-441 (2002
44. Emerick AJ, Kartje GL. Behavioral recovery and anatomical plasticity in adult rats after cortical lesion and treatment with monoclonal antibody IN-1. Behav. Brain Res. 152, 315-325 (2004
45. Seymour AB, Andrews EM, Tsai SY et al. Delayed treatment with monoclonal antibody IN-1 1 week after stroke results in recovery of function and corticorubral plasticity in adult rats. J. Cereb. Blood Flow Metab. 25, 1366-1375 (2005
46. Servida F, Ravasi C, Puricelli M et al. Decrease in neuroinflammation after immunisation with synthetic prion peptides in an animal model of scrapie. Vet. Res Comm. 31(Suppl. 1), 265-267 (2007
47. Sigurdsson EM, Brown DR, Daniels M et al. Immunization delays the onset of prion disease in mice. Am. J. Pathol. 161(1), 13-17 (2002
48. Schwarz A, Krätke O, Burwinkel M et al. Immunisation with a synthetic prion protein-derived peptide prolongs survival times of mice orally exposed to the scrapie agent. Neurosci. Lett. 350(3), 187-189 (2003
49. Magri G, Clerici M, Dall'Ara P et al. Decrease in pathology and progression of scrapie after immunisation with synthetic prion protein peptides in hamsters. Vaccine 23(22), 2862-2868 (2005
50. Pilon J, Loiacono C, Okeson D et al. Anti-prion activity generated by a novel vaccine formulation. Neurosci. Lett. 429(2-3), 161-164 (2007
51. Goni F, Knudsen E, Schreiber F et al. Mucosal vaccination delays or prevents prion infection via an oral route. Neuroscience 133(2), 413-421 (2005
52. Polymenidou M, Heppner FL, Pellicioli EC et al. Humoral immune response to native eukaryotic prion protein correlates with anti-prion protection. Proc. Natl Acad Sci. USA 101(2), 14670-14676 (2004
53. Muller CE, Iqbal J, Zimmermann H, Rollic A, Stephan H. Polyoxometalates - a new class of potent ecto-nucleoside triphosphate diphosphohydrolase (NTPDase) inhinitors. Bioorg. Med. Chem. Lett. 16(23), 5943-5947 (2006
54. Fernandez-Borges N, Brun A, Whitton JL et al. DNA vaccination can break immunological tolerance to PrP in wild-type mice and attenuates prion disease after intracerebral challenge. J. Virol. 80(20), 9970-9976 (2006
55. Bainbridge J, Jones N, Walker B. Multiple antigenic peptides facilitate generation of anti-prion antibodies. Clin. Exp. Immunol. 137(2), 298-304 (2004
56. Rosset MB, Ballerini C, Gregoire S et al. Breaking immune tolerance to the prion protein using prion protein peptides plus oligodeoxynucleotide-CpG in mice. J. Immunol. 172(9), 5168-5174 (2004
57. Spinner DS, Kascsak RB, Lafauci G et al. CpG oligodeoxynucleotide- enhanced humoral immune response and production of antibodies to prion protein PrPSc in mice immunized with 139A scrapie-associated fibrils. J. Leukoc. Biol. 81(6), 1374-1385 (2007
58. Kaiser-Schulz G, Heit A, Quintanilla-Martinez L et al. Polylactide-coglycolide microspheres co-encapsulating recombinant tandem prion protein with CpG-oligonucleotide break self-tolerance to prion protein in wild-type mice and induce CD4 and CD8 T cell responses. J. Immunol. 179(5), 2797-2807 (2007
59. Bade S, Frey A. Potential of active and passive immunizations for the prevention and therapy of transmissible spongiform encephalopathies. Exp. Rev. Vaccines 6(2), 153-168 (2007
60. Tal Y, Souan L, Cohen IR et al. Complete Freund's adjuvant immunization prolongs survival in experimental prion disease in mice. J. Neurosci. Res. 71(2), 286-290 (2003
61. Dudley ME, Wunderlich JR, Robbins PF et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumour lymphocytes. Science 298(5594), 850-854 (2002
62. Carnaud C, Bachy V. Cell-based immunotherapy of prion diseases by adoptive transfer of antigen-loaded dendritic cells or antigen-primed CD4+ T lymphocytes. Prion 4(2), 66-71 (2010
63. Gourdain P, Gre'goire S, Iken S et al. Adoptive transfer of T lymphocytes sensitized against the prion protein attenuates prion invasion in scrapie-infected mice. J. Immunol. 183, 6619-6628 (2009
64. Gregoire S, Logre C, Metharom P et al. Identification of two immunogenic domains of the prion protein - PrP - which activate class II-restricted T cells and elicit antibody responses against the native molecule. J. Leukoc. Biol. 76, 125-134 (2004
65. Iken S, Bachy V, Gourdain P et al. Th2-polarised PrP-specific transgenic T-cells confer partial protection against murine scrapie. PLoS Pathog. 7(9), e1002216 (2011
66. North RJ. Cyclophosphamide-facilitated adoptive immunotherapy. J. Exp. Med. 155(4), 1063-1074 (1982
67. Bachy V, Ballerini C, Gourdain P et al. Mouse vaccination with dendritic cells loaded with prion protein peptides overcomes tolerance and delays scrapie. J. Gen. Virol. 91, 809-820 (2010
68. Gabizon R, McKinley MP, Groth D, Prusiner SB. Immunoaffinity purification and neutralization of scrapie prion infectivity. Proc. Natl Acad. Sci. USA 85(18), 6617-6621 (1988
69. Vetrugno V, Cardinale A, Filesi I et al. KDEL-tagged anti-prion intrabodies impair PrP lysosomal degradation and inhibit scrapie infectivity. Biochem. Biophys. Res. Commun. 338(4), 1791-1797 (2005
70. Heppner FL, Musahl C, Arrighi I et al. Prevention of scrapie pathogenesis by transgenic expression of anti-prion protein antibodies. Science 294(5540), 178-182 (2001
71. White AR, Enever P, Tayebi M et al. Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature 2003 422(6927), 80-83 (2003
72. Sigurdsson EM, Sy MS, Li R et al. Anti-prion antibodies for prophylaxis following prion exposure in mice. Neurosci. Lett. 336(3), 185-187 (2003
73. Song CH, Furuoka H, Kim CL et al. Effect of intraventricular infusion of anti-prion protein monoclonal antibodies on disease progression in prion-infected mice. J. Gen. Virol. 89(Pt 6), 1533-1544 (2008
74. Yu Y, Zhang L, Li X et al. Differential effects of an O-GlcNAcase inhibitor on tau phosphorylation. PLoS ONE 7(4), e35277 (2012
75. Eghiaian F, Grosclaude J, Lesceu S et al. Insight into the PrPC→PrPSc conversion from the structures of antibody-bound ovine prion scrapie-susceptibility variants. Proc. Natl Acad. Sci. USA 101(28), 10254-10259 (2004
76. Kocisko DA, Priola SA, Raymond GJ et al. Species specificity in the cell-free conversion of prion protein to protease-resistant forms: a model for the scrapie species barrier. Proc. Natl Acad. Sci. USA 92(9), 3923-3927 (1995
77. Priola SA, Chabry J, Chan K. Efficient conversion of normal prion protein (PrP) by abnormal hamster PrP is determined by homology at amino acid 155. J. Virol. 75(10), 4673-4680 (2001
78. Hamilton RD, Foss AJ, Leach L. Establishment of a human in vitro model of the outer blood-renal barrier. J. Anatomy 211(6), 707-716 (2007
79. Amor S, Groome N, Linington C et al. Identification of epitopes of myelin oligodendrocyte glycoprotein for the induction of experimental allergic encephalomyelitis in SJL and Biozzi AB/H mice. J. Immunol. 153(10), 4349-4356 (1994
80. Mathisen P, Yu M, Johnson J, Drazba J, Tuohy V. Treatment of experimental autoimmune encephalomyelitis with genetically modified memory T cells. J. Exp. Med. 186(1), 159-164 (1997
81. Shaw M, Lorens J, Dhawan A et al. Local delivery of interleukin 4 by retrovirus-transduced T lymphocytes ameliorates experimental autoimmune encephalomyelitis. J. Exp. Med. 185, 1711-1714 (1997
82. Chen L, Hochwald G, Huang C et al. Gene therapy in allergic encephalomyelitis using myelin basic protein-specific T cells engineered to express latent transforming growth factor-b1. Proc. Natl Acad. Sci USA 95, 12516-12521 (1998
83. Morita Y, Yang J, Gupta R et al. Dendritic cells genetically engineered to express IL-4 inhibit murine collagen-induced arthritis. J. Clin. Invest. 107(10), 1275-1284 (2001
84. Wuertzer CA, Sullivan MA, Qiu X, Federoff HJ. CNS delivery of vectored prion-specific single-chain antibodies delays disease onset. Mol. Ther. 16(3), 481-486 (2008
85. Mabbott NA, Mackay F, Minns F, Bruce ME. Temporary inactivation of follicular dendritic cells delays neuroinvasion of scrapie. Nat. Med. 6, 719-720 (2000
86. Mabbott NA, Young J, McConnell I et al. Follicular dendritic cell dedifferentiation by treatment with an inhibitor of the lymphotoxin pathway dramatically reduces scrapie susceptibility. J. Virol. 77(12), 6845-6854 (2003
87. Montrasio F, Frigg R, Glatzel M et al. Impaired prion replication in spleens of mice lacking functional follicular dendritic cells. Science 288(5469), 1257-1259 (2000
88. Honda H, Sasaki K, Minaki H et al. Protease-resistant PrP and PrP oligomers in the brain in human prion diseases after intraventricular pentosan polysulfate infusion. Neuropathology 32(2), 124-132 (2012
89. Campana V, Zentilin L, Mirabile I et al. Development of antibody fragments for immunotherapy of prion diseases. Biochem J. 418(3), 507-15 (2009
90. Marchionni M, KirK C, Isaacs I et al. Neuregulins as potential drugs for neurological disorders. Cold Spring Harbor Symp. Quant. Biol. 61, 459-472 (1996
91. Dimayuga FO, Ding Q, Keller JN et al. The neuregulin GGF2 attenuates free radical release from activated microglial cells. J. Neuroimmunol. 136(1), 67-74 (2003
92. Brazier MW, Lewis V, Ciccotosto GD et al. Correlative studies support lipid peroxidation is linked to PrP(res) propagation as an early primary pathogenic event in prion disease. Brain Res. Bull. 68(5), 346-354 (2006
93. Carson MJ, Doose JM, Melchior B, Schmid CD, Ploix CC. CNS immune privilege: hiding in plain sight. Immunol. Rev. 213, 48-65 (2006
94. Johnston BL, Conly JM. Alemtuzumab and natalizumab: the monoclonal antibody story continues. Can. J. Infect. Dis. Med. Microbiol. 17(6), 327-329 (2006
95. Both L, Banyard AC, van Dolleweerd C et al. Passive immunity in the prevention of rabies. Lancet Infect. Dis. 12(5), 397-407 (2012
96. Azinovic I, DeNardo GL, Lamborn KR et al. Survival benefit associated with human anti-mouse antibody (HAMA) in patients with B-cell malignancies. Cancer Immunol. Immunother. 55(12), 1451-1458 (2006
97. Chadd HE, Chamow SM. Therapeutic antibody expression technology. Curr. Opin. Biotechnol. 12(2), 188-194 (2001
98. Marks JD, Hoogenboom HR, Bonnert TP et al. By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J. Mol. Biol. 222(3), 581-597 (1991
99. Schmitz U, Versmold A, Kaufmann P, Frank HG. Phage display: a molecular tool for the generation of antibodies - a review. Placenta 21(Suppl. A), S106-S112 (2000
100. Petri S, Kiaei M, Damiano M et al. Cell-permeable peptide antioxidants as a novel therapeutic approach in a mouse model of amyotrophic lateral sclerosis. J. Neurochem. 98(4), 1141-1148 (2006
101. Brazier MW, Doctrow SR, Masters CL et al. A manganese-superoxide dismutase/catalase mimetic extends survival in a mouse model of human prion disease. Free Radic. Biol. Med. 45(2), 184-192 (2008
102. Brazier MW, Volitakis I, Kavasnika M et al. Manganese chelation therapy extends survival in a mouse model of M1000 prion disease. J. Neurochem. 114(2), 440-451 (2010
103. Hill AF, Desbruslais M, Joiner S et al. The same prion strain causes vCJD and BSE. Nature 389(6650), 448-450 (1997
104. Mascelli MA, Zhou H, Sweet R et al. Molecular, biologic, and pharmacokinetic properties of monoclonal antibodies: impact of these parameters on early clinical development. J. Clin. Pharmacol. 47(5), 553-565 (2007
105. Asai DJ, Wilder JK. Making monoclonal antibodies. Methods Cell Biol. 37, 57-74 (1993
106. Wognam B, Lee T. Basic Cell Culture Protocols (Methods in Molecular Biology) volume 946. Helgason CD, Miller CL (Eds). Humana Press Inc., NY, USA 133-149 (2013
107. Moreira PI, Zhu Z, Wang X et al. Mitochondria: a therapeutic target in neurodegeneration. Biochim. Biophys. Acta 1802(1), 212-220 (2010
108. Bard F, Cannon C, Barbour R et al. Peripherally administered antibodies against amyloid b-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nature 6(8), 916-919 (2000